Tejara Capital Ltd Increases Position in Roivant Sciences Ltd. $ROIV

Tejara Capital Ltd boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 9.3% in the third quarter, HoldingsChannel reports. The firm owned 506,095 shares of the company’s stock after purchasing an additional 43,082 shares during the quarter. Roivant Sciences makes up approximately 4.0% of Tejara Capital Ltd’s holdings, making the stock its 7th largest holding. Tejara Capital Ltd’s holdings in Roivant Sciences were worth $7,657,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its stake in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after buying an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after acquiring an additional 34,341 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Roivant Sciences by 10.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,261 shares of the company’s stock worth $296,000 after acquiring an additional 2,385 shares during the period. Valeo Financial Advisors LLC bought a new stake in Roivant Sciences in the 2nd quarter valued at about $1,145,000. Finally, KLP Kapitalforvaltning AS boosted its stake in Roivant Sciences by 6.6% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 76,100 shares of the company’s stock valued at $858,000 after purchasing an additional 4,700 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Price Performance

ROIV opened at $21.62 on Friday. The business has a 50 day moving average price of $21.89 and a two-hundred day moving average price of $17.43. The company has a market capitalization of $15.04 billion, a price-to-earnings ratio of -38.61 and a beta of 1.22. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $23.91.

Insiders Place Their Bets

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 353,745 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.05, for a total value of $7,800,077.25. Following the sale, the insider directly owned 34,132,463 shares in the company, valued at approximately $752,620,809.15. The trade was a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mayukh Sukhatme sold 1,018,995 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the completion of the sale, the insider directly owned 20,267,429 shares of the company’s stock, valued at $440,005,883.59. The trade was a 4.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 12,332,392 shares of company stock valued at $266,393,645. 10.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of Roivant Sciences in a research note on Thursday, December 18th. The Goldman Sachs Group increased their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Leerink Partners lifted their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Roivant Sciences in a research report on Thursday, January 22nd. Finally, Citigroup raised their price target on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.